Annexon, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ANNX Nasdaq 2830 www.annexonbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Annexon, Inc.

Annexon Biosciences (ANNX) Buy Rating Retained - Apr 21st, 2026 3:14 pm
Annexon CEO Touts “Win Year” 2026 at Needham, Eyes GA Phase III Data and GBS FDA Filing - Apr 15th, 2026 3:02 pm
Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference - Apr 8th, 2026 2:05 pm
Wall Street Analysts See a 165.52% Upside in Annexon (ANNX): Can the Stock Really Move This High? - Apr 1st, 2026 7:55 am
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans? - Apr 1st, 2026 4:59 am
Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones - Mar 30th, 2026 2:01 pm
Are Medical Stocks Lagging American Well (AMWL) This Year? - Mar 23rd, 2026 7:40 am
Annexon Investor Day: ANX007 Targets C1q in Dry AMD GA as Phase III Readout Nears Q4 - Mar 18th, 2026 8:02 pm
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - Mar 16th, 2026 2:05 pm
Annexon Spotlights GA Phase III, GBS Regulatory Plans and ANX1502 Update at TD Cowen Conference - Mar 4th, 2026 3:48 am
Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference - Feb 24th, 2026 6:00 am
Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy - Feb 17th, 2026 6:00 am
Does Annexon’s EMA Filing For Tanruprubart Reshape The Bull Case For ANNX? - Jan 20th, 2026 8:10 am
Assessing Annexon (ANNX) Valuation After EMA Filing For Tanruprubart In Guillain Barre Syndrome - Jan 18th, 2026 8:10 am
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - Jan 16th, 2026 3:05 pm
Annexon Maps “Pivotal” 2026 at JPM Conference: ANX007 Phase 3 GA Readout, ANX005 Filings Ahead - Jan 14th, 2026 3:10 pm
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026 - Jan 12th, 2026 5:00 am
Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome - Jan 8th, 2026 6:00 am
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - Jan 7th, 2026 2:05 pm
Here Are Tuesday’s Top Wall Street Analyst Research Calls: AMETEK, Coty, Janus Henderson, Levi Strauss, Pool Corporation, Southern Copper, and More - Dec 23rd, 2025 6:13 am